Northwest Biotherapeutics, Inc. NWBO
0.16 USD -0.01 (-4.82%)
Nov 4, 2026, 3:24 PM EST
0.1573 Day range 0.1846
0.15 52-week range 0.32
- YTD
- -30.48%
- 1 year
- -36.04%
- Market cap
- 272.73M
- Revenue (ttm)
- 1.42M
- EPS (ttm)
- -0.03
- Shares out
- 153.41M
- YTD return
- -30.48%
- 1-year return
- -36.04%
- Volume
- 3.76M
- Avg volume
- 4.13M
- Open
- 0.169
- Previous close
- 0.168
- Day's range
- 0.1573 – 0.1846
- 52-week range
- 0.15 – 0.32
- Beta
- 0.55
- Analysts
- Buy
- Price target
- 5.00 (+3027.0%)
6M -0.0452 (-21.52%)
Key statistics
- Enterprise value
- 69.76M
- PEG ratio
- 0.00
- Price / sales
- 44.34
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -45.40%
- Free cash flow
- -84.42M
- Total cash
- 802.00K
- Total debt
- 21.09M
- Return on equity
- 0.00%
- Short % of float
- 15.09%
- 50-day average
- 0.407273
- 200-day average
- 0.457338
Analyst view
Consensus: buy
Buy
Price target (mean) 5.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NWBO Revenue — quarterly 200.00K
NWBO Net income — quarterly -26.83M
NWBO EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.02 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -0.02 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | -0.02 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.02 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2014 | Oppenheimer | down | Outperform | Perform |
| Oct 15, 2013 | Oppenheimer | init | — | Outperform |
| Sep 18, 2013 | Summer Street Research | init | — | Buy |
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nwbio.com
News
Northwest Biotherapeutics Announces Expansion of Its Technical Team 
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production 
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production 
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference 
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company 
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company 
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses 
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting 
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting 
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
Your note
Sign in to keep a note on NWBO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COGNATE BIOSERVICES, INC. | Beneficial Owner (10% or more) | Sale | Jun 29, 2015 | 18,460,390 |
| WOODFORD INVESTMENT MANAGEMENT LLP | Beneficial Owner (10% or more) | Ownership Statement | Nov 4, 2015 | 18,316,679 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Woodford Investment Management LLP | 20.79% | 25,915,937 | 13.99M | Sep 29, 2016 |
| Credit Suisse/ | 1.52% | 1,898,904 | 1.03M | Sep 29, 2016 |
| Vanguard Group, Inc. (The) | 1.11% | 1,378,939 | 744.63K | Sep 29, 2016 |
| Goldman Sachs Group, Inc. | 0.80% | 994,696 | 537.13K | Sep 29, 2016 |
| BlackRock Institutional Trust Company, N.A. | 0.58% | 717,911 | 387.67K | Sep 29, 2016 |
| Millennium Management LLC | 0.29% | 357,411 | 193.00K | Sep 29, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.78% | 968,768 | 561.88K | Jun 29, 2016 |
| Vanguard Extended Market Index Fund | 0.44% | 546,665 | 317.06K | Jun 29, 2016 |
| Fidelity Extended Market Index Fund | 0.13% | 158,536 | 53.90K | Aug 30, 2016 |
| Fidelity Total Market Index Fund | 0.05% | 60,544 | 20.58K | Aug 30, 2016 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.03% | 33,900 | 19.66K | Jun 29, 2016 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 27,004 | 9.18K | Aug 30, 2016 |